MohammedMahmoudMilhemMD

Hematologic Oncology, Melanoma, Sarcoma

Chief, Section of Oncology Deputy Director for Clinical Research and Clinical Services at Holden Comprehensive Cancer Center Professor of Internal Medicine Holden Family Chair in Experimental Therapeutics

Join to view full profile

Dr. Milhem is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Milhem's full profile

Already have an account?

Office
200 Hawkins Dr
Iowa City, IA 52242
Phone+1 319-356-2324

Fax+1 319-353-8383
Is this information wrong?

Education & Training

University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1997 - 2000
University of Jordan Faculty of MedicineClass of 1995

Certifications & Licensure

IA State Medical License 2006 - 2025
IL State Medical License 1997 - 2014

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
America's Top Doctors for Cancer Castle Connolly, 2011-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat Start of enrollment: 2009 Dec 01
Terminated
Phase 1, Phase 2
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas Start of enrollment: 2010 Sep 01
Completed
Phase 1
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free Start of enrollment: 2010 Jun 01
Completed
Phase 2
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2011 May 01
Terminated
Phase 2, Phase 3
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma Start of enrollment: 2011 Apr 01
Completed
Phase 2
Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors Start of enrollment: 2011 Jun 01
Unknown status
Phase 1
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
Terminated
Phase 4
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20
Completed
Phase 2
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Start of enrollment: 2013 Jul 31
Completed
Phase 2
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2013 May 01
Terminated
Phase 4
Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Ketogenic Diet Phase 1 for Head & Neck Cancer Start of enrollment: 2014 Jan 01
Terminated
Not Applicable
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma Start of enrollment: 2014 Jun 13
Completed
Phase 2
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Start of enrollment: 2014 Mar 21
Completed
Phase 3
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Oct 18
Completed
Phase 2
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases Start of enrollment: 2015 Feb 01
Terminated
Phase 2
TVEC and Preop Radiation for Sarcoma (4 ml Dose) Start of enrollment: 2015 Jul 13
Completed
Phase 1, Phase 2
NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy Start of enrollment: 2020 Feb 19
Active, not recruiting
Phase 2
Chlorpromazine and Standard of Care in Glioblastoma Start of enrollment: 2022 Jan 28
Active, not recruiting
Phase 1
Roles: Sponsor-Investigator, Contact, Principal Investigator
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial Start of enrollment: 2017 Jul 18
Active, not recruiting
Phase 1
Roles: Sponsor-Investigator, Principal Investigator, Contact
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) Start of enrollment: 2020 Nov 24
Recruiting
Early Phase 1
Roles: Principal Investigator, Sponsor-Investigator, Contact
Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS) Start of enrollment: 2024 Feb 01
Recruiting
Phase 1
Roles: Contact, Sponsor-Investigator, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
T* Imaging Assessment of Neoadjuvant Radiation Therapy Combined With Pharmacological Ascorbate in Extremity Soft-Tissue Sarcomas: A Pilot Study.
Lee, C., Petronek, M., Magnotta, V., Monga, V., Miller, B., Milhem, M., Allen, B.> ;The Iowa Orthopaedic Journal. 2023 Dec 1
1 citations
Clinical diagnostic and radiographic features of recurrent intracranial malignant triton tumor in an adult: illustrative case.
Ajmain Chowdhury, Alex Belzer, Nahom Teferi, Hend Al-Kaylani, Juan Vivanco-Suarez, Assim Saad Eddin, Kathryn Eschbacher, Mohammed Milhem, Patrick Hitchon> ;Journal of Neurosurgery. Case Lessons. 2023 Aug 21
3 citations
Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial.
Espen B Ellingsen, Steven O'Day, Artur Mezheyeuski, Agnieszka Gromadka, Trevor Clancy, Timothy S Kristedja, Mohammed Milhem, Yousef Zakharia> ;Clinical Cancer Research. 2023 Aug 15
8 citations
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, ...
Jason A Chesney, Igor Puzanov, Frances A Collichio, Parminder Singh, Mohammed M Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe, Theodor...> ;Journal for Immunotherapy of Cancer. 2023 May 1
3 citations
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.
Lisa A Kottschade, Gregory Russell Pond, Anthony J Olszanski, Yousef Zakharia, Evidio Domingo-Musibay, Ralph J Hauke, Brendan D Curti, Sarah Schober, Mohammed M Milhem...> ;Clinical Cancer Research. 2023 Jun 13
1 citations
The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma.
Natalie K Heater, Scott Okuno, Steven Robinson, Steven Attia, Mahesh Seetharam, Brittany L Siontis, Janet Yoon, Sant Chawla, Mohammed M Milhem, Varun Monga, Keith Skub...> ;Journal of Clinical Medicine. 2023 Mar 29
1 citations
Postoperative Echography for Optimization of Radiation Dosimetry in Patients with Uveal Melanoma Treated with Plaque Brachytherapy.
Elaine M Binkley, Benjamin A King, Daniel E Hyer, Asad Javed, Mohammed M Milhem, Connie J Hinz, Sarah L Mott, H Culver Boldt> ;Ophthalmology. Retina. 2023 Jul 1
3 citations
The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis.
Lawrence Liu, Carina Dehner, Nikhil Grandhi, Yang Lyu, Dana C Borcherding, John S A Chrisinger, Xiao Zhang, Jingqin Luo, Yu Tao, Amanda Parkes, Nam Q Bui, Elizabeth J ...> ;Genes. 2022 Oct 24
4 citations
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastat...
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, Mark Agulnik, Mohammed M Milhem, Suzanne George, Robin L Jones, Bartosz Chmielowski, Brian A Van Tine, Hussein Tawbi,...> ;European Journal of Cancer. 2022 Nov 1
2 citations
Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
Robert H I Andtbacka, Yan Wang, Robert H Pierce, Jean S Campbell, Melinda Yushak, Mohammed Milhem, Merrick Ross, Katie Niland, Robert D Arbeit, Sudha Parasuraman, Kris...> ;Cancer Research Communications. 2022 Aug 1
3 citations
Detection of Ferritin Expression in Soft Tissue Sarcomas With MRI: Potential Implications for Iron Metabolic Therapy.
Michael S Petronek, Ann M Tomanek-Chalkley, Varun Monga, Mohammed M Milhem, Benjamin J Miller, Vincent A Magnotta, Bryan G Allen> ;The Iowa Orthopaedic Journal. 2022 Jun 1
21 citations
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
Macarena I de la Fuente, Howard Colman, Mark Rosenthal, Brian A Van Tine, Danijela Levacic, Tobias Walbert, Hui K Gan, Maria Vieito, Mohammed M Milhem, Kathryn Lipford...> ;Neuro-Oncology. 2023 Jan 5
1 citations
Surgical management for giant bladder leiomyosarcoma.
Alexander A Hart, Charles H Schlaepfer, Neha Dhungana, Mohammed M Milhem, Vignesh T Packiam> ;Urology Case Reports. 2022 May 1
10 citations
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial.
Cohen, E., Nabell, L., Wong, D., Day, T., Daniels, G., Milhem, M., Deva, S., Jameson, M., Guntinas-Lichius, O., Almubarak, M., Strother, M., Whitman, E., Chisamore, M....> ;Clinical Cancer Research. 2022 Mar 15
Patient reported quality of life in young adults with sarcoma receiving care at a sarcoma center.
Jonathan R Day, Benjamin Miller, Bradley T Loeffler, Sarah L Mott, Munir Tanas, Melissa Curry, Jonathan Davick, Mohammed Milhem, Varun Monga> ;Frontiers in Psychology. 2022 Jan 1
1 citations
Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance.
Jeff Rytlewski, Qierra R Brockman, Rebecca D Dodd, Mohammed Milhem, Varun Monga> ;Cancer Drug Resistance. 2022 Jan 1
Presumed Melanoma of Unknown Primary Origin Metastatic to the Choroid Mimics Primary Uveal Melanoma.
John M Rieth, Randy Chris Bowen, Mohammed M Milhem, H Culver Boldt, Elaine M Binkley> ;Case Reports in Ophthalmology. 2021 Dec 28
2 citations
An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma
Merve Hasanov, Denái R. Milton, William H. Sharfman, Bret Taback, Lee D. Cranmer, Gregory A. Daniels, Lawrence E. Flaherty, Sigrun Hallmeyer, Mohammed M. Milhem, Lynn ...> ;Oncoimmunology. 2021 Oct 9
6 citations
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
Craig L. Slingluff, Karl D. Lewis, Robert H.I. Andtbacka, John R. Hyngstrom, Mohammed M. Milhem, Svetomir N. Markovic, Tawnya L. Bowles, Omid Hamid, Leonel Hernandez-A...> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
268 citations
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul C. Nathan, Jessica C. Hassel, Piotr Rutkowski, Jean-François Baurain, Marcus O. Butler, Max Schlaak, Ryan J. Sullivan, Sebastian Ochsenreither, Reinhard Dummer, J...> ;The New England Journal of Medicine. 2021 Sep 23
2 citations
Sustained response to imatinib in patient with extraskeletal myxoid chondrosarcoma and novel KIT mutation.
Brooke Jennings, John M. Rieth, Travis Snyders, Mohammed M. Milhem> ;BMJ Case Reports. 2021 Aug 26
14 citations
An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma.
Mark Agulnik, Brian C Schulte, Steven I. Robinson, Angela C. Hirbe, Kevin Kozak, Sant P. Chawla, Steven Attia, Alfred Rademaker, Hui Zhang, Susan Abbinanti, Rasima Ceh...> ;European Journal of Cancer. 2021 Jul 17
10 citations
Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremiti...
Varun Monga, Benjamin J. Miller, Munir R. Tanas, Sarag Boukhar, Bryan G. Allen, Carryn M. Anderson, Laura Stephens, Stacey Hartwig, Steven Varga, Jon Houtman, Lei Wang...> ;Journal for Immunotherapy of Cancer. 2021 Jul 1
38 citations
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Yousef Zakharia, Robert R. McWilliams, Olivier Rixe, Joseph J. Drabick, Montaser Shaheen, Kenneth F. Grossmann, Ravindra Kolhe, Rafal Pacholczyk, Ramses F. Sadek, Luci...> ;Journal for Immunotherapy of Cancer. 2021 Jun 11
20 citations
Current status of intralesional agents in treatment of malignant melanoma.
Misam Zawit, Umang Swami, Hassan Awada, Joyce Arnouk, Mohammed M. Milhem, Yousef Zakharia> ;Annals of Translational Medicine. 2021 Jun 1
Join now to see all

Journal Articles

Efficacy and Tolerability of Trabectedin in Elderly Patients with Sarcoma: Subgroup Analysis from a Phase 3, Randomized Controlled Study of Trabectedin or Dacarbazine ...
A Elias, M Milhem, S Patel, S M Schuetze, M L Hensley, Annals of Oncology

Lectures

Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naÃ¯ve to anti-PD-1 therapy.
2019 ASCO Annual Meeting - 6/1/2019
Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus granulocyte macrophage colony-stimulating ...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Mohammed Milhem Named Division Director of Hematology, Oncology, and Blood & Marrow TransplantationDecember 3rd, 2021
Identification and Treatment Key in Responding to COVID-19 Health Anxiety in ChildrenSeptember 4th, 2020
Exicure, Inc. : To Present at Jefferies 2020 Healthcare ConferenceMay 20th, 2020
Join now to see all

Hospital Affiliations

University of Iowa Hospitals and ClinicsIowa City, Iowa